Ghost Tree Capital’s Boston Scientific BSX Stock Holding History

Ghost Tree Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-300,000	Closed	-$6.49M	–	74
2016 Q4	$6.49M	Sell	300,000 -150,000	-33%	-$3.27M	1.56%	27
2016 Q3	$10.7M	Buy	450,000 +100,000	+29%	+$2.39M	1.74%	16
2016 Q2	$8.18M	Buy	+350,000	New	+$7.57M	2.36%	13

Other funds holding BSX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Ghost Tree Capital's BSX Position: Q4 2017 in Review

Ghost Tree Capital sold out of Boston Scientific (BSX) in Q4 2017, closing a stake of 275,000 shares — an estimated $8.02M sold.

Ghost Tree Capital first reported a position in BSX in Q2 2014 and held it in 8 quarters. The position peaked at $11.2M in Q1 2017. 632 funds tracked by Wall St. Rank hold BSX as of Q4 2017.

Ghost Tree Capital reported no remaining Boston Scientific position as of Q4 2017 after selling out during the quarter.
Ghost Tree Capital sold 275,000 Boston Scientific shares in Q4 2017, an estimated $8.02M.
Ghost Tree Capital first reported a position in Boston Scientific in Q2 2014 and held it in 8 quarters.
Ghost Tree Capital's Boston Scientific position peaked at $11.2M in Q1 2017.
632 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2017.

Based on Ghost Tree Capital's 13F filing for Q4 2017, filed 14 Feb 2018.